Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
2011
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer
2011
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer
2009
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
2008
Targeted therapies for breast cancer
2011
Molecular Stratification of Triple-Negative Breast Cancers
2011
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
2010
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
2009
Triple negative breast cancer: unmet medical needs
2010
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
2010
Trastuzumab containing regimens for early breast cancer
2012
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
2011
Biologic markers determine both the risk and the timing of recurrence in breast cancer
2011
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
2013
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
2015
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004
Triple-Negative Breast Cancer
2010 Standout
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
2011
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
2009
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial
2008
Polymer-drug conjugates: Recent development in clinical oncology
2008
Prodrug Strategies in Anticancer Chemotherapy
2007
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
2010
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Gemcitabine Plus Cisplatin for the Treatment of Metastatic Breast Cancer
2002
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Longitudinal Study Evaluating the Association Between Physician Burnout and Changes in Professional Work Effort
2016
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
2015
Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: A European Society of Breast Cancer Specialists database analysis
2015
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
2011
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
2012
Impact of Burnout on Self-Reported Patient Care Among Emergency Physicians
2015
Burnout Syndrome Among Medical Practitioners Across India: A Questionnaire-Based Survey
2016
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Changes in Burnout and Satisfaction With Work-Life Balance in Physicians and the General US Working Population Between 2011 and 2014
2015 Standout
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Cardiovascular effects of systemic cancer treatment
2010
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
2014
Clonal evolution in cancer
2012 StandoutNature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
2004
Chemotherapy in Early Breast Cancer: When, How and Which One?
2014
Burnout and associated factors among members of the Society of Gynecologic Oncology
2015
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
2009 Standout
Diagnosing the decline in pharmaceutical R&D efficiency
2012 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
The cancer genome
2009 StandoutNature
Deconstructing the molecular portraits of breast cancer
2010
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
2010
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Practical Approach to Triple-Negative Breast Cancer
2017
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
PARP inhibitors stumble in breast cancer
2011
Prevalence of Burnout Among Physicians
2018 Standout
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
2015
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
2011
Breast Cancer Treatment
2019 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2010
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
2018 StandoutNobel
Burnout, career satisfaction, and well-being among US neurologists in 2016
2017
Metabolic reprogramming and cancer progression
2020 StandoutScience
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
The resurgence of covalent drugs
2011
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
A Heck–Matsuda Process for the Synthesis of β‐Arylethenesulfonyl Fluorides: Selectively Addressable Bis‐electrophiles for SuFEx Click Chemistry
2016 StandoutNobel
Stress, satisfaction and burnout amongst A ustralian and N ew Z ealand radiation oncologists
2014
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
2017 StandoutNobel
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
2013
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
2009
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of John Pippen being referenced
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2009
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
2009
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
2012
Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer
2004
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
2010
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
2011
Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
2003
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma
2005
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
2007
Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast Cancer
2004
Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors
2005
Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
2002
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
2006
Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
2010
Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).
2009
Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial
2002
Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
2010
Satisfaction With Work-Life Balance and the Career and Retirement Plans of US Oncologists
2014
Burnout and Career Satisfaction Among US Oncologists
2014
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
2009
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
2009
Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
2007
Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel
2004 Nobel
Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
2010